Mergers and Acquisitions (Tables)

9 Months Ended

Sep. 30, 2014

Medistem, Inc.

Acquisition Date Fair Value Consideration Transferred

The fair value of the total consideration transferred was $24,995. The acquisition date fair value of each class of consideration transferred is presented below:



Cash	$	4,920
Common shares	19,368
Settlement of promissory notes	707
	$	24,995

Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date

The preliminary estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash	$	8
Intangible assets	4,824
Total assets acquired	4,832
Accounts payable	644
Accrued compensation and benefits	85
Other accrued expenses	150
Total liabilities assumed	879
Net assets acquired	3,953
Goodwill	21,042
Total consideration	$	24,995

Trans Ova Genetics, LC

Business Acquisition [Line Items]

Acquisition Date Fair Value Consideration Transferred

The fair value of the total consideration transferred, including the noncontrolling interest in a majority-owned subsidiary of Trans Ova, was $123,519. The acquisition date fair value of each class of consideration transferred and noncontrolling interest is presented below:



Cash	$	63,165
Common shares	32,802
Deferred cash consideration	20,115
Total consideration transferred	116,082
Fair value of noncontrolling interest	7,437
Total	$	123,519

Estimated Fair Value of Assets Acquired and Liabilities Assumed at Acquisition Date

The preliminary estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash	$	960
Trade receivables	17,996
Related party receivables	1,219
Inventory	17,256
Prepaid expenses and other	590
Property, plant and equipment	18,686
Intangible assets	24,100
Other non-current assets	147
Total assets acquired	80,954
Accounts payable	3,317
Accrued compensation and benefits	913
Other accrued liabilities	271
Deferred revenue	2,420
Lines of credit	4,091
Related party payables	1,246
Long term debt	9,090
Total liabilities assumed	21,348
Net assets acquired	59,606
Goodwill	63,913
Total consideration	$	123,519

Medistem and Trans Ova

Business Acquisition [Line Items]

Condensed Pro forma Financial Information

The following unaudited condensed pro forma financial information for the three months ended September 30, 2014 and 2013 and the nine months ended September 30, 2014 and 2013 is presented as if each of the acquisitions had been consummated on January 1, 2013:



	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
	Pro forma
Revenues	$	31,506		$	22,335		$	88,628		$	65,822
Loss before income taxes	(51,858		)	15,453			(98,745		)	(27,303		)
Net loss	(51,858		)	15,453			(98,768		)	(27,303		)
Net loss attributable to the noncontrolling interests	1,192			721			3,246			1,667
Net loss attributable to Intrexon	(50,666		)	16,174			(95,522		)	(25,636		)
Accretion of dividends on redeemable convertible preferred stock	—			(4,044		)	—			(18,391		)
Undistributed earnings allocated to preferred shareholders	—			(3,132		)	—			—
Net loss attributable to common shareholders	$	(50,666	)	$	8,998		$	(95,522	)	$	(44,027	)